Zelboraf (Vemurafenib) 240mg Tablets | China Version | GLT

Generic Information: Zelboraf (Vemurafenib) — Roche China Version (佐博伏)

Zelboraf is sold in China under the Chinese brand name 佐博伏, the registered trade name of vemurafenib marketed by Roche Holding AG. This page covers the 240 mg film-coated tablet in a 56-tablet box, the same 240 mg strength used in the twice-daily dosing schedule. Vemurafenib received marketing approval in China in 2017 as the first BRAF inhibitor to reach the Chinese market, and it was subsequently included in the national medical insurance drug list, making it reimbursable for eligible melanoma patients. As China's first and, for a period, only approved single-agent BRAF inhibitor, 佐博伏 holds a foundational place in the country's precision oncology landscape for BRAF V600-mutant melanoma.

What Is Zelboraf (佐博伏) Used For?

Zelboraf is indicated in China for the treatment of unresectable or metastatic melanoma in patients whose tumors test positive for the BRAF V600 mutation, using an approved detection method. This is a clinically important niche because BRAF-mutant melanoma carries a worse prognosis than wild-type disease, and Chinese patients have a distinct subtype distribution — with a higher proportion of acral and mucosal melanoma than Western populations — for whom this targeted therapy remains a necessary option. 佐博伏 is the only single-agent BRAF inhibitor approved in China, giving it a unique role for patients who cannot tolerate or are contraindicated for combination BRAF/MEK inhibitor regimens.

How Does Zelboraf (佐博伏) Work?

Zelboraf is a potent, selective inhibitor of the mutated BRAF V600E kinase. In BRAF-mutant melanoma, a single amino-acid substitution in the BRAF protein keeps it permanently switched on, sending a continuous growth signal down the MAPK pathway. By binding the mutant kinase and blocking its activity, vemurafenib halts this aberrant signaling, slowing tumor proliferation and inducing tumor regression. The drug is designed to preferentially inhibit the mutated enzyme rather than the normal one, which is why confirming BRAF V600 mutation status is an absolute prerequisite for treatment and why it must never be used in wild-type BRAF melanoma.

Indications

Zelboraf (佐博伏) is indicated for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma, as determined by an approved detection method. It is not indicated for patients with BRAF wild-type melanoma.

Dosage

The recommended dose is 960 mg (four 240 mg tablets) twice daily, taken approximately 12 hours apart, with or without food. The first dose of the day is taken in the morning and the second in the evening. Tablets are swallowed whole with water and must not be chewed or crushed. Treatment is continued until disease progression or unacceptable toxicity, with dose adjustments managed according to the severity of adverse reactions and any QT-interval prolongation.

Side Effects

Common adverse reactions include arthralgia, rash, alopecia, fatigue, photosensitivity, nausea, pruritus, and skin papillomas. A distinctive risk of this class is the emergence of cutaneous squamous cell carcinoma and keratoacanthoma, so patients undergo dermatologic monitoring before and during therapy. Other serious events include QT prolongation, liver enzyme elevation, and severe skin reactions. Liver function and electrocardiograms are monitored at baseline and periodically during treatment.

Storage

Store 佐博伏 tablets at no more than 30°C, protected from moisture, in the original packaging. Keep out of the reach of children and do not use beyond the expiry date.

Why Choose the GLT?

The China-registered 佐博伏 is priced far more affordably than the same originator molecule in the United States, where a month of brand-name Zelboraf costs many times more for cash-paying patients. For patients and institutions who need the authentic Roche product, sourcing the China version through a Hong Kong-licensed supplier such as GLT offers a dependable route to the genuine originator at a substantially lower cost. GLT provides batch documentation, confirms availability, and supports both individual patients and institutions with transparent, competitive pricing.

How to Order Zelboraf (佐博伏)

To order Zelboraf (佐博伏), contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please share the required quantity, your destination country, and any documentation needs so we can confirm current availability and delivery terms.

FAQ

Is 佐博伏 the same as Zelboraf? Yes. 佐博伏 is the Chinese brand name of Zelboraf (vemurafenib), marketed by Roche.

Is Zelboraf covered by insurance in China? Yes. Vemurafenib was added to the national medical insurance drug list as a reimbursable category-B product, which substantially lowers out-of-pocket cost for eligible patients.

Why is BRAF testing required? Zelboraf only benefits patients whose tumors carry the BRAF V600 mutation, so a confirmatory test is mandatory before treatment.

What makes the China version different? It is the same Roche originator molecule, registered and marketed in China as 佐博伏, offering access to the authentic product at a more accessible price than Western markets.